Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - DYNASIL CORP OF AMERICA | Financial_Report.xls |
| 10-Q - FORM 10-Q - DYNASIL CORP OF AMERICA | v320539_10q.htm |
| EX-32.1 - EXHIBIT 32.1 - DYNASIL CORP OF AMERICA | v320539_ex32-1.htm |
| EX-31.1B - EXHIBIT 31.1(B) - DYNASIL CORP OF AMERICA | v320539_ex31-1b.htm |
| EX-31.1A - EXHIBIT 31.1(A) - DYNASIL CORP OF AMERICA | v320539_ex31-1a.htm |
Contacts:
Patty Kehe
Corporate Secretary
Dynasil Corporation of America
Phone: (617) 668-6855
pkehe@dynasil.com
David Calusdian
Executive Vice President and Partner
Sharon Merrill
617.542.5300
DYSL@InvestorRelations.com
Dynasil Corporation of America Reports Third Quarter Fiscal 2012 Results
- Company Hosts Conference Call at 5:00 p.m. (ET) Today
Watertown, MA, August 14, 2012 – Dynasil
Corporation of America (NASDAQ: DYSL), a leading developer of sensing, detection and analysis technology for homeland
security, medical and industrial applications, today announced financial results for the fiscal 2012 third quarter ended June
30, 2012.
Net revenue for the third quarter of fiscal 2012 increased 2.2% to $12.4 million from $12.2 million for the third quarter of fiscal
2011. Contract Research segment revenue grew to $6.6 million compared with $6.3 million in the same period a year earlier. Revenue
from the Company’s Products and Technology segment was $5.9 million, essentially unchanged from the third quarter of 2011.
“Our Contract Research business remained strong in the third quarter, as revenue increased 4.4% and we maintained a solid
funded project backlog that extends into 2014,” said Peter Sulick, Dynasil’s Chairman and Interim CEO and President.
“In addition, we are successfully broadening our Contract Research customer base by targeting new agencies and non-governmental
opportunities. Our Products and Technology revenue has remained steady throughout the year as we complete our product refresh
activities and continue development of our dual mode detector technology.”
Gross margin for the third quarter of 2012 totaled $5.2 million, or 41.5% of net revenue, compared with $5.1 million, or 42.3%
of revenue, for the same period of fiscal 2011.
Selling, general and administrative (“SG&A”) expenses for the third quarter of fiscal 2012 totaled $5.2 million
versus $4.9 million for the comparable period in fiscal 2011. This does, however, represent a decline of approximately $350,000
from the Company’s SG&A expenses in the second quarter of this year. Over the past 12 months, the Company has been incurring
expense to refresh certain of its aging products within our Dynasil Products business, provide incentives to management, expand
its intellectual property portfolio and invest in the biomedical initiative in Rochester, MN. The development work on the Dynasil
Products refresh is largely complete and these products will be available for sale in 2013. The Company’s intellectual property
portfolio has expanded from 40 issued, 3 provisional and 18 pending U.S. Patents as of June 30, 2011 to 43 issued, 25 provisional
and 37 pending U.S. Patents as of June 30, 2012. There are a number of exciting activities within the biomedical initiative.
The net loss for the third quarter of 2012 was $48,130 or $0.00 per share, compared with net income of $1.0 million, or $0.07 per diluted share, for the quarter ended June 30, 2011, which included approximately $1,045,000 in Research & Experimentation tax credits.
Recent Highlights
| · | $3 Million Financing Agreement: On July 31, 2012, Dynasil
completed a $3 million subordinated note financing with Massachusetts Capital Resource Company (MCRC) pursuant to a Note Purchase
Agreement. Proceeds from the Note Purchase Agreement were used to repay in full approximately $1.9 million in promissory notes
issued in connection with a put right exercised by a former owner of RMD Instruments, LLC, which Dynasil acquired in 2008. The
remaining $1.1 million of proceeds will be used for the Company’s working capital. |
| · | Framework for collaborations with Mayo Clinic: Dynasil signed a technology collaboration agreement with Mayo Clinic, providing the framework under which the organizations intend to advance early-stage innovations to patented products for therapeutic applications. Their first collaborative project focuses on a therapeutic hypothermia core cooling technology designed to protect the brain during cardiac arrest and traumatic brain injury. |
“We believe that our biomedical technologies may have
significant commercial potential, and our goal is to monetize the most promising opportunities,” Sulick said. “Toward
that end, we have filed provisional patents for certain technologies and have begun exploring the possibility of spinning out
at least one of these technologies into an independent entity. Our goal would be to maintain a substantial interest in the entity
while bringing in complementary expertise to advance the technologies to market.”
Conference Call Information
Dynasil Corporation will host a conference call for investors and analysts at 5:00
p.m. ET today. The call will be hosted by Chairman and Interim CEO and President Peter Sulick and Chief Financial Officer Richard
Johnson. Those who wish to listen to the conference call should visit the Investor Information
section of the Company’s website at www.dynasil.com. The call also may be accessed
by dialing (877) 407-5790 or (201) 689-8328. For interested individuals unable to join the live conference call, a webcast replay
will be available on the Company’s website for one year.
About Dynasil
Dynasil Corporation of America (NASDAQ: DYSL) develops and manufactures detection and analysis technology, precision instruments and optical components for the homeland security, medical and industrial markets. Combining world-class technology with expertise in research and materials science, Dynasil is commercializing products including dual-mode radiation detection solutions for Homeland Security and commercial applications, probes for medical imaging and sensors for non-destructive testing. Dynasil has an impressive and growing portfolio of issued and pending U.S. patents. The Company is based in Watertown, Massachusetts, with additional operations in Mass., Minn., NY, NJ and the United Kingdom. More information about the Company is available at www.dynasil.com.
Forward-looking Statements
This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements regarding future events and our future results are based on current expectations, estimates, forecasts, and projections and the beliefs and assumptions of our management. These forward-looking statements may be identified by the use of words such as “may,” “could,” “expect,” “estimate,” “anticipate,” “continue” or similar terms, though not all forward-looking statements contain such words. The actual results of the future events described in such forward-looking statements could differ materially from those stated in such forward-looking statements due to a number of important factors. These factors that could cause actual results to differ from those anticipated or predicted include, without limitation, our ability to develop and commercialize our products, including our dual mode detectors and the development of new technologies including at Dynasil Biomedical, the size and growth of the potential markets for our products and our ability to serve those markets, the rate and degree of market acceptance of any of our products, general economic conditions, costs and availability of raw materials and management information systems, our ability to obtain and maintain intellectual property protection for our products, competition, the loss of key management personnel, litigation, the effect of governmental regulatory developments, the availability of financing sources, our ability to identify and execute on acquisition opportunities and integrate such acquisitions into our business, and seasonality, as well as the uncertainties set forth in the Company’s Annual Report on Form 10-K and from time to time in the Company's other filings with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
| Dynasil Corporation of America and Subsidiaries | ||||||||
| Consolidated Balance Sheets | ||||||||
| 30-Jun | 30-Sep | |||||||
| 2012 | 2011 | |||||||
| ASSETS | (Unaudited) | |||||||
| Current Assets | ||||||||
| Cash and cash equivalents | $ | 2,986,312 | $ | 4,479,840 | ||||
| Accounts receivable, net | 7,643,129 | 5,837,139 | ||||||
| Inventories | 3,151,255 | 3,250,539 | ||||||
| Cost in excess of billings | -0- | 408,240 | ||||||
| Deferred tax asset | 1,225,446 | 1,119,800 | ||||||
| Prepaid expenses and other current assets | 1,151,428 | 771,564 | ||||||
| Total current assets | 16,157,570 | 15,867,122 | ||||||
| Property, Plant and Equipment, net | 5,020,442 | 4,860,328 | ||||||
| Other Assets | ||||||||
| Intangibles, net | 5,885,922 | 6,374,329 | ||||||
| Goodwill | 13,287,807 | 13,330,182 | ||||||
| Deferred financing costs, net | 120,722 | 150,656 | ||||||
| Total other assets | 19,294,451 | 19,855,167 | ||||||
| Total Assets | $ | 40,472,463 | $ | 40,582,617 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current Liabilities | ||||||||
| Current portion of long-term debt | $ | 1,857,143 | $ | 1,859,728 | ||||
| Obligation to repurchase stock | 1,857,546 | -0- | ||||||
| Accounts payable | 3,186,198 | 2,088,395 | ||||||
| Accrued expenses and other liabilities | 1,977,990 | 2,298,460 | ||||||
| Contingent consideration | 141,337 | 183,713 | ||||||
| Total current liabilities | 9,020,214 | 6,430,296 | ||||||
| Long-term Liabilities | ||||||||
| Long-term debt, net of current portion | 7,555,446 | 8,985,442 | ||||||
| Deferred tax liability | 811,705 | 924,837 | ||||||
| Total long-term liabilities | 8,367,151 | 9,910,279 | ||||||
| Temporary Equity | -0- | 2,000,000 | ||||||
| Stockholders' Equity | 23,085,098 | 22,242,042 | ||||||
| Total Liabilities and Stockholders' Equity | $ | 40,472,463 | $ | 40,582,617 | ||||
Dynasil Corporation of America and Subsidiaries
Consolidated Statement of Operations and Comprehensive Income (Loss)
(Unaudited)
| Three Months Ended | Three Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2012 | 2011 | 2012 | 2011 | |||||||||||||
| Net revenue | $ | 12,415,772 | $ | 12,153,175 | $ | 37,279,808 | $ | 35,896,030 | ||||||||
| Cost of revenue | 7,259,466 | 7,012,611 | 21,733,906 | 21,136,257 | ||||||||||||
| Gross profit | 5,156,306 | 5,140,564 | 15,545,902 | 14,759,773 | ||||||||||||
| Selling, general and administrative expenses | 5,180,292 | 4,911,288 | 15,679,544 | 12,978,126 | ||||||||||||
| Income (loss) from operations | (23,986 | ) | 229,276 | (133,642 | ) | 1,781,647 | ||||||||||
| Interest expense, net | 140,246 | 148,563 | 375,855 | 461,916 | ||||||||||||
| Income (loss) before income tax benefit | (164,232 | ) | 80,713 | (509,497 | ) | 1,319,731 | ||||||||||
| Income tax benefit | (116,102 | ) | (946,165 | ) | (367,047 | ) | (478,342 | ) | ||||||||
| Net income (loss) | $ | (48,130 | ) | $ | 1,026,878 | $ | (142,450 | ) | $ | 1,798,073 | ||||||
| Net Income (loss) | $ | (48,130 | ) | $ | 1,026,878 | $ | (142,450 | ) | $ | 1,798,073 | ||||||
| Other comprehensive income (loss): | ||||||||||||||||
| Foreign currency translation | 31,222 | 47,118 | (29,138 | ) | 185,712 | |||||||||||
| Total comprehensive income (loss) | $ | (16,908 | ) | $ | 1,073,996 | $ | (171,588 | ) | $ | 1,983,785 | ||||||
| Net income (loss) | $ | (48,130 | ) | $ | 1,026,878 | $ | (142,450 | ) | $ | 1,798,073 | ||||||
| Dividends on preferred stock | -0- | -0- | -0- | 116,646 | ||||||||||||
| Net income (loss) applicable to common stockholders | $ | (48,130 | ) | $ | 1,026,878 | $ | (142,450 | ) | 1,681,427 | |||||||
| Dividend add back due to preferred stock conversion | -0- | -0- | -0- | 116,646 | ||||||||||||
| Net income (loss) for diluted income per common share | $ | (48,130 | ) | $ | 1,026,878 | $ | (142,450 | ) | $ | 1,798,073 | ||||||
| Basic net income (loss) per common share | $ | (0.00 | ) | $ | 0.07 | $ | (0.01 | ) | $ | 0.12 | ||||||
| Diluted net income (loss) per common share | $ | (0.00 | ) | $ | 0.07 | $ | (0.01 | ) | $ | 0.12 | ||||||
| Weighted average shares outstanding | ||||||||||||||||
| Basic | 14,275,293 | 15,394,811 | 14,878,360 | 14,448,875 | ||||||||||||
| Diluted | 14,275,293 | 15,748,591 | 14,878,360 | 14,802,655 | ||||||||||||